Gene Therapy RZ-001 Shows Positive Early Clinical Data for Recurrent Glioblastoma

Rznomics Inc. has announced interim results from its Phase 1/2a clinical trial for RZ-001, an RNA-based gene therapy designed to treat recurrent glioblastoma. The data indicates a manageable safety profile, with no significant adverse events reported. Some patients in the study demonstrated prolonged tumor recurrence inhibition and disease control, offering potential hope for those with this aggressive brain tumor.